Therapeutics News

Calcium channel blocker use was associated with an average 39% higher odds of glaucoma, as well as thinner inner retinal thickness, in a cross-sectional study of UK Biobank data.

LAS VEGAS — Visus Therapeutics completed one clinical trial for Brimochol PF, a once-daily drop for presbyopia, earlier this year and is currently enrolling patients for a second trial, a company executive said at Vision Expo West.

LAS VEGAS — The recent FDA approval of Ryzumvi for the reversal of drug-induced mydriasis has created the opportunity to perform more dilated, comprehensive eye exams, according to Paul M. Karpecki, OD, FAAO.

OKYO Pharma has completed patient enrollment for the randomized portion of its phase 2 clinical trial of OK-101, a topical treatment for dry eye disease, the company announced in a press release.

Pilocarpine hydrochloride 1.25% administered twice daily yielded statistically greater near-vision improvements than a control vehicle, while maintaining the safety profile of once-daily administration, according to research.

Atsena Therapeutics has dosed the first patient in its open-label, phase 1/2 LIGHTHOUSE study to evaluate the subretinal ATSN-201 injection for X-linked retinoschisis, according to a company press release.

The FDA has issued a warning to consumers not to purchase and to immediately stop use of Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops because of bacterial and fungal contamination.

Ocuphire Pharma announced plans to meet with the FDA in the fourth quarter of 2023 to advance a phase 3 regulatory path for APX3330, an investigational treatment for diabetic retinopathy and diabetic macular edema.

Presbyopia is part of the body’s natural aging process, meaning that everybody who lives long enough will eventually become presbyopic.

Harrow announced it will begin marketing and selling Vigamox, a fluoroquinolone antibiotic eye drop for bacterial conjunctivitis, following completion of the product’s new drug application transfer.